Clinical efficacy study on calming liver and restraining Yang formula in treating patients with mild or moderate degree of essential hypertension

Zhongguo Zhongyao Zazhi

Volumn 35, Issue 6, 2010, Pages 776-781

  Zhong, Guangwei ^a   Luo, Yanhong ^a   Xiang, Lingli ^a   Xie, Yong ^b   Xie, Qiying ^a   Li, Yunhui ^a   Zhang, Cheng ^c  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b THE FIRST PEOPLE S HOSPITAL OF CHENZHOU   (China)

^c Second People's Hospital of Hunan Province   (China)

Author keywords

Calming liver and restraining the yang formula; Clinical study; Essential hypertension; Mild or moderate degree

Indexed keywords

AMLODIPINE; ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; CALCITONIN; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LIPID; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; YANG FORMULA;

ANGIOTENSIN BLOOD LEVEL; ARTICLE; BITTER TASTE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; BLOOD PRESSURE VARIABILITY; BORDERLINE HYPERTENSION; CALCITONIN BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DISEASE SEVERITY; DIZZINESS; DRUG EFFICACY; DRUG METABOLISM; ESSENTIAL HYPERTENSION; HEART RATE; HUMAN; HYPERACTIVITY; INFLAMMATION; KNEE; LIPID BLOOD LEVEL; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; LIVER; MAJOR CLINICAL STUDY; MOUTH; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; SYMPTOM; TRIACYLGLYCEROL BLOOD LEVEL; WEAKNESS;

ADULT; AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; ANXIETY; BLOOD PRESSURE; CHOLESTEROL; CHOLESTEROL, HDL; DRUGS, CHINESE HERBAL; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; PHYTOTHERAPY; TRIGLYCERIDES;

EID: 77953516833     PISSN: 10015302     EISSN: None     Source Type: Journal    
DOI: 10.4268/cjcmm20100626     Document Type: Article

References (14)

1. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC) [J]. Eur Heart J, 2007,28(12):1462.
2. Wang R, Zhao Y, He X, et al. Impact of hypertension on health-related quality of life in a population-based study in Shanghai, China[J]. Public Health, 2009, 123(8):534.
3. Shintani Y, Kikuya M, Hara A, et al. Ambulatory blood pressure, blood pressure variability and the prevalence of carotid artery alteration: The ohasama study[J]. J Hypertens, 2007,25: 1704.
4. Xie Hehui, Shen Fuming, Zhang Xiaofei, et al. Blood pressure variability, baroreflex sensitivity and organ damage in spontaneously hypertensive rats treated with various antihypertensive drugs [J]. Eur J Pharmacol, 2006,543(1/3):77.
5. Paolo Verdecchia, Fabio Angeli, Roberto Gattobigio, et al. Impact of blood pressure variability on cardiac and cerebrovascular complications in hypertension [J]. Am J Hypertens, 2007,20 (2):154.
6. Mendall M A, St rachan D P, Butland B K, et al. C-reactive protein: Relation to total mortality, cardiovascular mortality and cardiovascular risk factors in men [J]. Eur Heart J, 2000,21 (19):1584.
7. Ferrario C M, Trask A J, Jessup J A. Advances in the biochemical and functional roles of angiotensin converting enzyme 2 and angiotensin-(1-7) in the regulation of cardiovascular function [J]. Am J Physiol Heart Circ Physiol, 2005, 289(6):2281.
8. Li D, Chen B M, Peng J, et al. Role of anandamide transporter in regulating calcitonin gene-related peptide production and blood pressure in hypertension[J]. J Hypertens, 2009,27(6):1224.